A series of controversial policy changes directed by the HHS secretary have left experts fearful of the future implications ...
In an interview, Chief Financial Officer Robin Kramer said the combined cash flow from Biogen and Apellis will not only help ...
It's the biggest life sciences private fund ever raised, coming in nearly 40% larger than its Blackstone predecessor vehicle.
Colorado drugmaker Ambrosia Biosciences has landed $100 million to pursue an oral obesity drug it’s hoping can compete with a ...
Constant leadership changes and erratic decision-making have left the biopharmaceutical industry feeling its chief regulator ...
Shares of Immunovant, Alto and Oric Pharmaceuticals fell this week on clinical trial updates. Elsewhere, Orca Bio’s cell ...
The deal secures two sleep disorder drugs that would fill a hole in the company’s portfolio and intensify a competition with ...
The company, led by Ron Renaud, raised $1 billion in venture funding to develop a competitor to Wegovy and Zepbound that’s ...
As clinical trials grow more complex, so does the volume of data that requires medical and operational review. Phase III trials now generate an average of 3.6 million data points—three times the ...
Despite hitting key goals across three late-stage studies, the drug, which targets the “OX40” ligand, raises safety and ...
A collaboration “across multiple therapeutic areas” could net the Hong Kong-based biotech more than $2 billion as Lilly seeks ...
The trial is tied to a post-marketing commitment that FDA Commissioner Martin Makary put in place last year for all approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results